Inventiva Reports Q1 2026 Financial Results and Confirms Q4 2026 Phase 3 NATiV3 Topline Results

Inventiva S.A. reported its financial results for the first quarter of 2026. As of March 31, 2026, the company held €75.0 million in cash and cash equivalents, plus €121.5 million in short-term deposits, totaling €196.5 million. This represents a decrease from the €230.9 million held at the end of 2025, primarily due to operating expenses related to the lanifibranor development program. Inventiva estimates its current cash runway will fund operations until the middle of the first quarter of 2027. This runway could potentially extend to the third quarter of 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company reported no revenue for the quarter. The most significant clinical update is the confirmation that topline results from the NATiV3 pivotal Phase 3 clinical trial, evaluating lanifibranor in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected in the fourth quarter of 2026. Management will participate in several upcoming investor conferences in June 2026 to discuss these developments.